Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

Amarin (AMRN) is set to report Q2 2025 earnings on July 30, with investor attention on its Vascepa/Vazkepa sales, which are anticipated to show a decline in the U.S. due to generic competition, offset by substantial growth in European markets. The Zacks Consensus Estimate projects Q2 revenue at $45.2 million and a loss of 60 cents per share, with operating expenses likely reduced by cost-cutting measures. A recent licensing deal with Recordati for EU Vazkepa commercialization, including a $25 million upfront payment and projected $70 million in cost savings, is expected to bolster Amarin's cash position, despite the company's earnings model not conclusively predicting a Q2 beat.

Analysis

Amarin Corporation is approaching its second-quarter 2025 earnings report at a significant strategic inflection point, defined by a stark divergence in its product's geographic performance. While U.S. sales of its sole drug, Vascepa, are expected to continue their decline due to sustained generic competition, this is contrasted by expectations of substantial revenue growth from its European counterpart, Vazkepa, particularly in the U.K. and Spain. The recent exclusive licensing agreement with Recordati for Vazkepa's commercialization across Europe marks a pivotal shift in strategy. This deal provides an immediate $25 million upfront payment, potential for an additional $150 million in milestones, and is projected to generate approximately $70 million in cost savings over the next year, significantly improving Amarin's cash position and de-risking its European operations. This strategic realignment appears to be resonating with the market, as evidenced by the stock's 60.7% year-to-date rally, which stands in sharp contrast to the industry's 0.5% decline. However, despite this optimism and a history of mixed earnings surprises, consensus estimates for the quarter are pegged at a loss of 60 cents per share on $45.2 million in revenue, and forecasting models indicate an Earnings ESP of 0.00%, suggesting an earnings beat is not conclusively predicted.

Key Decisions for Investors

• Investors should assess Amarin's value based on its new strategic direction, focusing on the execution of the Recordati partnership and realization of projected cost savings rather than on the legacy issue of declining U.S. sales.
• Given the stock's significant 60.7% year-to-date appreciation, it may be prudent to protect gains ahead of the earnings release, as the neutral earnings model forecast (0.00% ESP) sets a high bar for a positive surprise to fuel further upside.
• Closely monitor management's forward-looking guidance on the Vazkepa sales trajectory under the new European licensing model, as this, along with updates on cash preservation, will be the primary driver of the equity's performance post-earnings.